Clinical Trials
390
Active:331
Completed:43
Trial Phases
4 Phases
Phase 1:172
Phase 2:13
Phase 3:20
+1 more phases
Drug Approvals
44
CANADA:22
Drug Approvals
- Prev
- 1
- 2
- 3
- Next
Clinical Trials
Distribution across different clinical trial phases (210 trials with phase data)• Click on a phase to view related trials
Phase 1
172 (81.9%)Phase 3
20 (9.5%)Phase 2
13 (6.2%)Phase 4
5 (2.4%)A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology
Active, not recruiting
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 2000
- Registration Number
- NCT06043700
- Locations
- 🇺🇸
Eisai Site #3, Clermont, Florida, United States
🇺🇸Eisai Site #1, Lady Lake, Florida, United States
🇺🇸Eisai Site #2, District Heights, Maryland, United States
A Study to Determine the Absolute Bioavailability and the Absorption, Metabolism, and Elimination Properties of Carbon-14 (14C)E7386 in Healthy Male Participants
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: E7386 TabletDrug: (14C)E7386 CapsuleDrug: (14C)E7386
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 15
- Registration Number
- NCT05607537
- Locations
- 🇬🇧
Labcorp Clinical Research Unit, Leeds, United Kingdom
A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets Compared to an E7386 Immediate Release (IR) Tablet in Healthy Adult Participants
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Eisai Limited
- Registration Number
- NCT04840927
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: [14C]E7090
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 8
- Registration Number
- NCT04493255
- Locations
- 🇬🇧
Covance Clinical Research Unit, Leeds, United Kingdom
A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal Seizures
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 243
- Registration Number
- NCT04257604
- Prev
- 1
- 2
- 3
- 4
- 5
- 10
- Next
News
No news found